Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | SignaBlok to Highlight SCHOOL Therapeutic Peptides at the 2015 Essential Protein Engineering SummitPreclinical studies of novel peptide inhibitors (SCHOOL peptides) will be presented in an oral session. Presentation will highlight company's approach to targeted peptide delivery and support development of programs in oncology, sepsis and arthritis.
By: SignaBlok, Inc. By 2018, the global Peptide Therapeutics market is expected to reach over $25 billion. SignaBlok's presentation highlights a novel model of cell signaling, the Signaling Chain HOmoOLigomerization (SCHOOL) model, and related inhibitory peptides (SCHOOL peptides) that employ new, ligand-independent mechanisms of action. Nanotechnology- Oral Presentation: Wednesday, May 6, 2015 2nd Annual Peptide Therapeutics – Conquering Disease / Therapeutics Stream Session Title: Peptide Advances Ligand-Independent Inhibitory Peptides (SCHOOL Peptides) in Medicine: Recent Advances and Future Perspectives 11:55 AM ET Seaport World Trade Center, 200 Seaport Blvd, Boston About SignaBlok SignaBlok is developing a new class of therapies – SCHOOL peptides, the innovative modulatory peptides that can be rationally designed for nearly any cell surface receptor and have broad potential to treat and prevent a wide range of serious diseases with unmet clinical needs. SignaBlok is also developing a nanotechnology that enables targeted delivery of SCHOOL peptides and other therapies and/or imaging agents, aiming to improve efficacy, reduce dose, and allow image-guided therapy. Additional information about SignaBlok is available at www.signablok.com. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|